ZA200407985B - 1-(4-Piperidinyl) benzimidazolones as histamine H3antagonists. - Google Patents
1-(4-Piperidinyl) benzimidazolones as histamine H3antagonists.Info
- Publication number
- ZA200407985B ZA200407985B ZA200407985A ZA200407985A ZA200407985B ZA 200407985 B ZA200407985 B ZA 200407985B ZA 200407985 A ZA200407985 A ZA 200407985A ZA 200407985 A ZA200407985 A ZA 200407985A ZA 200407985 B ZA200407985 B ZA 200407985B
- Authority
- ZA
- South Africa
- Prior art keywords
- benzimidazolones
- histamine
- piperidinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37346702P | 2002-04-18 | 2002-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200407985B true ZA200407985B (en) | 2005-10-19 |
Family
ID=29736058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200407985A ZA200407985B (en) | 2002-04-18 | 2004-10-04 | 1-(4-Piperidinyl) benzimidazolones as histamine H3antagonists. |
Country Status (17)
Country | Link |
---|---|
US (1) | US7220735B2 (xx) |
EP (1) | EP1494671B1 (xx) |
JP (2) | JP4563800B2 (xx) |
KR (1) | KR20040099449A (xx) |
CN (1) | CN100360130C (xx) |
AR (1) | AR040406A1 (xx) |
AT (1) | ATE529112T1 (xx) |
AU (1) | AU2003223631B2 (xx) |
CA (1) | CA2482551C (xx) |
IL (1) | IL164583A (xx) |
MX (1) | MXPA04010172A (xx) |
MY (1) | MY132566A (xx) |
NZ (1) | NZ535764A (xx) |
PE (1) | PE20040464A1 (xx) |
TW (1) | TW200305409A (xx) |
WO (1) | WO2003103669A1 (xx) |
ZA (1) | ZA200407985B (xx) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
PL373889A1 (en) * | 2002-04-18 | 2005-09-19 | Schering Corporation | (1-4-piperidinyl)benzimidazole derivatives useful as histamine h3 antagonists |
MXPA04010172A (es) * | 2002-04-18 | 2005-02-03 | Schering Corp | 1-(4-piperidinil)benzimidazolonas como antagonistas de histamina h3). |
BR0312322A (pt) * | 2002-06-28 | 2005-04-12 | Euro Celtique Sa | Compostos, composições, métodos para o tratamento da dor em um animal, da incontinência urinária em um animal, de uma úlcera em um animal, de sìndrome de intestino irritável em um animal, da doença inflamatória do intestino em um animal, métodos para a inibição da função de vr1 em uma célula, kits e métodos para a preparação de uma composição |
US7332508B2 (en) * | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
JP2006528939A (ja) | 2003-04-23 | 2006-12-28 | グラクソ グループ リミテッド | ピペラジン誘導体ならびに神経および精神疾患の治療のためのその使用 |
US20050119266A1 (en) * | 2003-10-01 | 2005-06-02 | Yan Shi | Pyrrolidine and piperidine derivatives as factor Xa inhibitors |
CA2550012A1 (en) * | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same and use |
US7622579B2 (en) | 2004-06-28 | 2009-11-24 | Janssen Pharmaceutica Nv | Hetero isonipecotic modulators of vanilloid VR1 receptor |
TW200633990A (en) * | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
AU2006218404A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
MX2007016523A (es) * | 2005-06-20 | 2008-03-06 | Schering Corp | Piperidinas sustituidas ligadas a carbono y derivados de las mismas utiles como antagonistas de hsitamina h3. |
MX2008000115A (es) | 2005-06-20 | 2008-03-18 | Schering Corp | Derivados de piperidina utiles como antagonistas de histamina h3. |
WO2007016496A2 (en) * | 2005-08-02 | 2007-02-08 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
ES2397275T3 (es) * | 2005-08-04 | 2013-03-05 | Sirtris Pharmaceuticals, Inc. | Derivados de imidazopiridina como agentes moduladores de la sirtuína |
EP1931665A1 (en) * | 2005-09-20 | 2008-06-18 | Schering Corporation | 1-[[1-[(2-amin0-6-methyl-4-pyridinyl)methyl]-4-flu0r0-4-piperidinyl,]carbonyl]-4-[2-(2-pyridinyl)-3h-imidaz0[4, 5-b]pyridin-3-yl]piperidine useful as histamine h3 antagonist |
US7879880B2 (en) * | 2005-12-21 | 2011-02-01 | Schering Corporation | Substituted aniline derivatives useful as histamine H3 antagonists |
BRPI0620255A2 (pt) * | 2005-12-21 | 2011-11-08 | Schering Corp | uso de agentes redutores de colesterol e/ou antagonista/agonista inverso do receptor de h3 |
PE20071162A1 (es) * | 2005-12-21 | 2007-11-30 | Schering Corp | Combinacion de un antagonista/agonista inverso de h3 y un supresor del apetito |
KR20080087833A (ko) * | 2005-12-21 | 2008-10-01 | 쉐링 코포레이션 | 히스타민 h3 길항제로서 유용한 페녹시피페리딘 및 이의유사체 |
WO2007130712A1 (en) * | 2006-01-31 | 2007-11-15 | Janssen Pharmaceutica, Nv | Substituted dipiperidine as ccr2 antagonists for the treatment of inflammatory diseases |
US7728031B2 (en) * | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
WO2008045564A2 (en) * | 2006-10-12 | 2008-04-17 | Epix Delaware, Inc. | Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor |
KR20090127902A (ko) * | 2007-03-02 | 2009-12-14 | 쉐링 코포레이션 | 벤즈이미다졸 유도체 및 이의 사용방법 |
CL2008001822A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
BRPI0819093A2 (pt) * | 2007-11-01 | 2017-05-02 | Sirtris Pharmaceuticals Inc | compostos moduladores de sirtuína |
MX2010005186A (es) * | 2007-11-08 | 2010-05-27 | Sirtris Pharmaceuticals Inc | Tiazolopiridinas solubilizadas. |
RU2010128543A (ru) | 2007-12-11 | 2012-01-20 | Сайтопатфайндер, Инк. (Jp) | Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов |
US8771643B2 (en) | 2008-01-04 | 2014-07-08 | Schabar Research Associates Llc | Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound |
US8343997B2 (en) | 2008-12-19 | 2013-01-01 | Sirtris Pharmaceuticals, Inc. | Thiazolopyridine sirtuin modulating compounds |
AU2011261375B2 (en) | 2010-06-04 | 2016-09-22 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
JP2014114212A (ja) * | 2011-03-29 | 2014-06-26 | Dainippon Sumitomo Pharma Co Ltd | 新規ベンズイミダゾール誘導体 |
WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
US10112929B2 (en) | 2015-03-09 | 2018-10-30 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
US11739070B2 (en) | 2018-01-19 | 2023-08-29 | Idorsia Pharmaceuticals Ltd. | C5A receptor modulators |
CA3134613A1 (en) | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
US10639315B1 (en) | 2019-05-21 | 2020-05-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating Alzheimer's disease |
US10898493B2 (en) | 2019-04-12 | 2021-01-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease |
US10639314B1 (en) | 2019-04-30 | 2020-05-05 | LA PharmaTech Inc. | Method of treating Alzheimer's disease |
US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
US10966989B2 (en) | 2019-04-12 | 2021-04-06 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
US11389458B2 (en) | 2019-04-12 | 2022-07-19 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease |
CA3137393A1 (en) * | 2019-04-30 | 2020-11-05 | Jianmin Wang | A method of treating mental, behavioral, cognitive disorders |
CN110105263A (zh) * | 2019-05-13 | 2019-08-09 | 常州大学 | 一种阿米卡星中间体的合成方法 |
US11331307B2 (en) | 2020-07-15 | 2022-05-17 | Schabar Research Associates, Llc | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn |
US11324727B2 (en) | 2020-07-15 | 2022-05-10 | Schabar Research Associates, Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
WO2022268935A2 (en) * | 2021-06-23 | 2022-12-29 | F. Hoffmann-La Roche Ag | Novel process |
US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0730037B2 (ja) | 1987-03-13 | 1995-04-05 | 第一製薬株式会社 | ピリミジニルプロピオン酸誘導体 |
JP2807577B2 (ja) * | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
JP3859738B2 (ja) * | 1993-05-26 | 2006-12-20 | 大日本住友製薬株式会社 | キナゾリノン誘導体 |
FR2725986B1 (fr) * | 1994-10-21 | 1996-11-29 | Adir | Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP0786997A4 (en) * | 1994-10-27 | 1998-03-11 | Merck & Co Inc | MUSCARINE ANAGONISTS |
US5574044A (en) * | 1994-10-27 | 1996-11-12 | Merck & Co., Inc. | Muscarine antagonists |
GB9521781D0 (en) * | 1995-10-24 | 1996-01-03 | Merck Sharp & Dohme | Therapeutic agents |
US6211199B1 (en) * | 1995-11-17 | 2001-04-03 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases |
WO1997019074A1 (en) * | 1995-11-17 | 1997-05-29 | Hoechst Marion Roussel, Inc. | Substituted 4-(1h-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases |
MY116130A (en) | 1996-08-16 | 2003-11-28 | Schering Corp | Treatment of upper airway allergic responses |
US5869479A (en) * | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
DE19952146A1 (de) | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
ATE387439T1 (de) * | 2000-09-20 | 2008-03-15 | Schering Corp | Substituierte imidazole als duale histamin h1 und h3 agonisten oder antagonisten |
PE20020507A1 (es) | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
EP1373251A2 (en) | 2001-03-13 | 2004-01-02 | Schering Corporation | Non-imidazole compounds as histamine h3 antagonists |
EP1386920A4 (en) * | 2001-04-20 | 2005-09-14 | Banyu Pharma Co Ltd | DERIVATIVES OF BENZIMIDAZOLONE |
MXPA04010172A (es) * | 2002-04-18 | 2005-02-03 | Schering Corp | 1-(4-piperidinil)benzimidazolonas como antagonistas de histamina h3). |
-
2003
- 2003-04-16 MX MXPA04010172A patent/MXPA04010172A/es active IP Right Grant
- 2003-04-16 NZ NZ535764A patent/NZ535764A/en not_active IP Right Cessation
- 2003-04-16 PE PE2003000387A patent/PE20040464A1/es not_active Application Discontinuation
- 2003-04-16 KR KR10-2004-7016552A patent/KR20040099449A/ko not_active Application Discontinuation
- 2003-04-16 EP EP03719770A patent/EP1494671B1/en not_active Expired - Lifetime
- 2003-04-16 AU AU2003223631A patent/AU2003223631B2/en not_active Ceased
- 2003-04-16 MY MYPI20031425A patent/MY132566A/en unknown
- 2003-04-16 CA CA002482551A patent/CA2482551C/en not_active Expired - Fee Related
- 2003-04-16 US US10/414,943 patent/US7220735B2/en not_active Expired - Fee Related
- 2003-04-16 AR AR20030101341A patent/AR040406A1/es unknown
- 2003-04-16 JP JP2004510788A patent/JP4563800B2/ja not_active Expired - Fee Related
- 2003-04-16 CN CNB038137801A patent/CN100360130C/zh not_active Expired - Fee Related
- 2003-04-16 WO PCT/US2003/011696 patent/WO2003103669A1/en active Application Filing
- 2003-04-16 AT AT03719770T patent/ATE529112T1/de not_active IP Right Cessation
- 2003-04-17 TW TW092108926A patent/TW200305409A/zh unknown
-
2004
- 2004-10-04 ZA ZA200407985A patent/ZA200407985B/xx unknown
- 2004-10-14 IL IL164583A patent/IL164583A/en not_active IP Right Cessation
-
2006
- 2006-03-22 JP JP2006079808A patent/JP2006206603A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN1658875A (zh) | 2005-08-24 |
EP1494671B1 (en) | 2011-10-19 |
KR20040099449A (ko) | 2004-11-26 |
AR040406A1 (es) | 2005-04-06 |
IL164583A (en) | 2010-05-17 |
PE20040464A1 (es) | 2004-07-24 |
IL164583A0 (en) | 2005-12-18 |
ATE529112T1 (de) | 2011-11-15 |
CA2482551A1 (en) | 2003-12-18 |
EP1494671A1 (en) | 2005-01-12 |
JP4563800B2 (ja) | 2010-10-13 |
AU2003223631A1 (en) | 2003-12-22 |
TW200305409A (en) | 2003-11-01 |
JP2006206603A (ja) | 2006-08-10 |
US20040048843A1 (en) | 2004-03-11 |
JP2005529161A (ja) | 2005-09-29 |
CA2482551C (en) | 2009-08-11 |
WO2003103669A1 (en) | 2003-12-18 |
US7220735B2 (en) | 2007-05-22 |
AU2003223631B2 (en) | 2006-07-20 |
CN100360130C (zh) | 2008-01-09 |
MXPA04010172A (es) | 2005-02-03 |
MY132566A (en) | 2007-10-31 |
NZ535764A (en) | 2007-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200407985B (en) | 1-(4-Piperidinyl) benzimidazolones as histamine H3antagonists. | |
ZA200409339B (en) | Novel benzimidazole derivatives. | |
ZA200407984B (en) | (1-4-Piperidinyl) benzimidazole derivatives usefulas histamine H3 antagonists. | |
AP2331A (en) | Triazole derivatives as vasopressin antagonists. | |
AU2003257094A1 (en) | Substituted benzimidazole compounds | |
GB0318570D0 (en) | Banking systems | |
HK1068494A1 (en) | Transducer. | |
HK1080745A1 (en) | Angiogenesis inhibitors | |
AU2003281950A1 (en) | Emulsifier-free microgel | |
AU2003902860A0 (en) | Benzimidazole compounds | |
AU2003231872A1 (en) | Imidazolium cxcr3 inhibitors | |
AU2002335176A8 (en) | Laminating system | |
AU2003222206A1 (en) | Novel benzimidazole compounds | |
IL175438A0 (en) | 4-substituted imidazoles | |
IL175440A0 (en) | 5-substituted imidazoles | |
TW519030U (en) | Structure for tool set | |
AU2003237945A1 (en) | Crystalline (r)-2-(4-amidinophenylaminomethyl)-1-methyl-5-(1-(carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl)-benzimidazole, and the use thereof as antithrombotic agents | |
ZA200408338B (en) | Heterocyclic compounds. | |
ZA200306866B (en) | Matches. | |
ZA200207924B (en) | Combination tool. | |
ZA200309277B (en) | Research system. | |
ITRN20020007A1 (it) | Dispositivo di copertura per utensili di piallatrici. | |
ITRN20020004U1 (it) | Dispositivo di copertura per utensili di piallatrici. | |
ITGE20020015A1 (it) | Astuccio per occhiali di emergenza. | |
TW519944U (en) | Improved structure for tool rack |